These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 17468869)
21. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Alyea EP; Kim HT; Ho V; Cutler C; DeAngelo DJ; Stone R; Ritz J; Antin JH; Soiffer RJ Biol Blood Marrow Transplant; 2006 Oct; 12(10):1047-55. PubMed ID: 17067911 [TBL] [Abstract][Full Text] [Related]
22. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447 [TBL] [Abstract][Full Text] [Related]
23. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005]. Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910 [TBL] [Abstract][Full Text] [Related]
24. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369 [TBL] [Abstract][Full Text] [Related]
25. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. Komatsu T; Narimatsu H; Yoshimi A; Kurita N; Kusakabe M; Hori A; Murashige N; Matsumura T; Kobayashi K; Yuji K; Tanaka Y; Kami M Ann Hematol; 2007 Jan; 86(1):49-54. PubMed ID: 17036221 [TBL] [Abstract][Full Text] [Related]
26. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967 [TBL] [Abstract][Full Text] [Related]
27. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144 [TBL] [Abstract][Full Text] [Related]
28. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors. Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651 [TBL] [Abstract][Full Text] [Related]
29. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020 [TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen. Resnick IB; Aker M; Tsirigotis P; Shapira MY; Abdul-Hai A; Bitan M; Gesundheit B; Amar A; Ackerstein A; Samuel S; Slavin S; Or R Bone Marrow Transplant; 2007 Nov; 40(10):957-64. PubMed ID: 17846604 [TBL] [Abstract][Full Text] [Related]
31. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation. Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449 [TBL] [Abstract][Full Text] [Related]
34. Engraftment and survival following hematopoietic stem cell transplantation for osteopetrosis using a reduced intensity conditioning regimen. Tolar J; Bonfim C; Grewal S; Orchard P Bone Marrow Transplant; 2006 Dec; 38(12):783-7. PubMed ID: 17086207 [TBL] [Abstract][Full Text] [Related]
35. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. Miyakoshi S; Kami M; Tanimoto T; Yamaguchi T; Narimatsu H; Kusumi E; Matsumura T; Takagi S; Kato D; Kishi Y; Murashige N; Yuji K; Uchida N; Masuoka K; Wake A; Taniguchi S Transplantation; 2007 Aug; 84(3):316-22. PubMed ID: 17700155 [TBL] [Abstract][Full Text] [Related]
36. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Lutz C; Massenkeil G; Nagy M; Neuburger S; Tamm I; Rosen O; Dörken B; Arnold R Bone Marrow Transplant; 2008 May; 41(9):805-12. PubMed ID: 18195682 [TBL] [Abstract][Full Text] [Related]